Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Targeted Multiplex Validation Of Csf Proteomic Biomarkers: Implications For Differentiation Of Pcnsl From Tumor-free Controls And Other Brain Tumors

Targeted multiplex validation of CSF proteomic biomarkers: implications for differentiation of PCNSL from tumor-free controls and other brain tumors

Jingjing Ma1, Zhiguang Lin1, Yaqi Zhang2

  • 1Department of Hematology, Huashan Hospital, Fudan University, Shanghai, China.

Frontiers in Immunology
|August 15, 2024

Related Experiment Videos

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

7.8K
Quantitative Proteomics Workflow using Multiple Reaction Monitoring Based Detection of Proteins from Human Brain Tissue
11:49

Quantitative Proteomics Workflow using Multiple Reaction Monitoring Based Detection of Proteins from Human Brain Tissue

Published on: August 28, 2021

4.4K
On-Site Sampling and Extraction of Brain Tumors for Metabolomics and Lipidomics Analysis
06:48

On-Site Sampling and Extraction of Brain Tumors for Metabolomics and Lipidomics Analysis

Published on: May 31, 2020

5.9K

View abstract on PubMed

Summary
This summary is machine-generated.

This study developed a cerebrospinal fluid (CSF) proteomic panel for diagnosing primary central nervous system lymphoma (PCNSL). The panel accurately differentiates PCNSL from other brain tumors and controls, offering a less invasive diagnostic tool.

Area of Science:

  • Neuro-oncology
  • Proteomics
  • Biomarker Discovery

Background:

  • Primary central nervous system lymphoma (PCNSL) diagnosis is challenging due to imaging similarities with other brain tumors and invasive biopsy requirements.
  • Current diagnostic methods for PCNSL often involve invasive procedures like stereotactic brain lesion biopsy, which are not always feasible or definitive.

Purpose of the Study:

  • To validate previous proteomic profiling of cerebrospinal fluid (CSF) in PCNSL.
  • To develop and validate a novel CSF-based proteomic panel for accurate diagnosis and differentiation of PCNSL.

Main Methods:

  • Targeted proteomics analysis using liquid chromatography tandem-mass spectrometry (LC-MS/MS) on CSF samples.
  • Collected CSF from 30 PCNSL patients, 30 with other brain tumors, and 31 tumor-free controls.
Keywords:
cerebrospinal fluid (CSF)diffuse large B-cell lymphoma (DLBCL)liquid chromatography tandem-mass spectrometry (LC-MS/MS)

Related Experiment Videos

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

7.8K
Quantitative Proteomics Workflow using Multiple Reaction Monitoring Based Detection of Proteins from Human Brain Tissue
11:49

Quantitative Proteomics Workflow using Multiple Reaction Monitoring Based Detection of Proteins from Human Brain Tissue

Published on: August 28, 2021

4.4K
On-Site Sampling and Extraction of Brain Tumors for Metabolomics and Lipidomics Analysis
06:48

On-Site Sampling and Extraction of Brain Tumors for Metabolomics and Lipidomics Analysis

Published on: May 31, 2020

5.9K
  • Selected and optimized proteomic panels for diagnostic accuracy.

    • Main Results:

    • The developed proteomic panels achieved high diagnostic accuracy, with an Area Under the Curve (AUC) of 0.873 for PCNSL vs. controls and 0.937 for PCNSL vs. other brain tumors.
    • Pathway analysis revealed distinct molecular signatures associated with PCNSL diagnosis and differentiation, including extracellular matrix interactions and signaling pathways.
    • The CSF proteomic panel demonstrated significant potential for distinguishing PCNSL from other neurological conditions.

    Conclusions:

    • A CSF-based proteomic panel offers a promising, less invasive approach for accurate PCNSL diagnosis and differentiation.
    • This proteomic signature may overcome limitations of current diagnostic techniques, potentially improving patient management and outcomes.
    • Further clinical validation is warranted to integrate this proteomic panel into routine diagnostic workflows for PCNSL.
    primary central nervous system lymphoma (PCNSL)
    targeted proteomics